NAVLIN by EVERSANA is a single, integrated platform that combines data, software and insights to answer your most challenging price and access questions.
We help you plan and evaluate strategies to achieve success in U.S. and global markets.
NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.
NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.
NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.
NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.
NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.
NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.
NAVLIN’s new release makes it easier to navigate the most complex pricing decisions. It provides enhancements across the full lifecycle and is optimized for early access and launch support.
The new AI assistant is now available across the platform and features natural language, AI-driven querying of the pricing database. Those who are software users will see enhancements to predictability models.
NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.
NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.
NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.
NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.
NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.
NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.
NAVLIN’s new release makes it easier to navigate the most complex pricing decisions. It provides enhancements across the full lifecycle and is optimized for early access and launch support.
The new AI assistant is now available across the platform and features natural language, AI-driven querying of the pricing database. Those who are software users will see enhancements to predictability models.
650+
+99%
<24
4,000+
24x7
99.5%
U.S. President Donald Trump has surprised the global industry with a plan to impose a new 25% tariff on pharmaceutical importsThe announcement follows the recent implementation of a 10% additional duty on all imports from China and a 25% additional levy on imports from Mexico and CanadaThe president did not mention whether or not the latest tariff applies to all countries, but said the levy would increase over time
It's now just two weeks until the World Evidence, Pricing, and Access (EPA) Congress, taking place March 5 to 6, 2025, at the RAI Congress Centre in AmsterdamThe congress promises valuable insights from industry experts, including value-based pricing, real-world evidence, digital health, patient engagement, and biosimilarsAs a media partner, NAVLIN Daily's dedicated team will be on-site and reporting on the event, bringing you invaluable insights from speakers and experts. As a valued NAVLIN customer, you can use our NAVLIN50 registration discount code for a 50% discount
The French Senate has adopted the Social Security Financing Bill (PLFSS) for 2025, however, it still needs to promulgated and published in the Official GazetteeAccording to the adopted bill, the safeguard clause threshold (M amount) has been set at EUR 27.25 billion, rather than the previously expected EUR 27.89 billion. This threshold represents the maximum reimbursed drug expenditure before triggering contributions from pharmaceutical companies. A key provision of the safeguard clause is that no company’s contribution will exceed 10% of its turnover from reimbursed drugs in FranceThe bill also raises the rebate cap for generics and certain non-generic drugs from 40% to 50%, expands this allowance to biosimilars, and shortens the biosimilar substitution waiting period to one year
Generic Aadhaar, an India-based pharmaceutical firm providing affordable generic medicines, has announced an ambition to reach all 1.4 billion Indians with high-quality, affordable medicines by the end of 2025 by expanding its network to 5,000+ storesThe firm offers all its formulations at an 80% discount across various therapeutic segments, including cardiology, diabetology, oncology, pediatrics, gastroenterology, dermatology, and neurology, with medicines for epilepsy, Parkinson's, and Alzheimer's “This relentless focus on accessibility and affordability is a direct challenge to the barriers that have long hindered equitable healthcare in India,” Arjun Deshpande, Founder of Generic Aadhaar, told NAVLIN Daily
Join us at EVERSANA’s inaugural Pharma Pricing & Contracting Innovation Conference (PCIC), which will take place March 3-4 at the Hyatt Place St. PetersburgInteract with a cohort of peers and industry executives where you will be inspired and educated as you discover new solutions and case studies, network with your peers, and experience the latest products and innovations aimed at improving decision making for pricing & market access professionalsConference registration includes access to workshops and conference content; complimentary breakfast, lunch, and snacks; an exclusive networking dinner; and copies of all presentations following the event
The Haute Autorité de Santé (HAS) in France has released its Strategic Project 2025-2030, succeeding the previous 2019-2024 strategyThe plan outlines HAS aims to enhance economic assessments to better inform public decision-making, address rising healthcare costs, and collaborate with stakeholders and research institutionsWith the implementation of EU HTA Regulation 2021/2282, HAS seeks to strengthen its European presence, influence health policy, and actively contribute to shaping healthcare standards
France is cutting the price of Novo Nordisk's Victoza from EUR 87.49 to EUR 60.26 per box of two pre-filled pens, from February 15 onwardThe price cut comes as French authorities make moves to enforce stricter reimbursement conditions for GLP-1 receptor agonistsA generic version of Victoza was recently registered in France, adding potential competition in the GLP-1 market. However, there are currently no registered generics for Ozempic (semaglutide) or Trulicity (dulaglutide)
The Organisation of Pharmaceutical Producers of India (OPPI) has hailed the Union Budget 2025's patient-centric approach, particularly the expansion of cancer care facilities to enhance accessibility to cancer care, import duty exemptions on 36 essential medicines, the inclusion of 13 patient assistance programs (PAPs), and efforts to strengthen India’s healthcare workforceSpeaking to NAVLIN Daily, OPPI Director General Anil Matai commended these developments and emphasized the need for ongoing cooperation between the government and the pharmaceutical industryOPPI told NAVLIN DAILY that ahead of the budget, it had emphasized the need for policy-level clarifications, particularly regarding the expansion of import duty exemptions for lifesaving and oncology medications to reduce treatment costs
The European Commission has launched the first request submission period for joint scientific consultations (JSCs) under the HTA Regulation (EU) 2021/2282, running from February 3 to March 3, 2025Health technology developers (HTDs) can apply for JSCs for medicinal products, with consultation slots starting in June, July, and September 2025Products must be in the early planning stage and expected to undergo a Joint Clinical Assessment (JCA), with selection based on factors like unmet medical need and innovation potential
The new UK-wide Innovative Licensing and Access Pathway (ILAP) was launched on 30th January. It will open to new applications in March 2025 The National Health Insurance Service (NHIS) of Korea has launched this year’s purchase amount monitoring efforts to inform price limit revisions for certain drugs China’s centralized procurement system has expanded across borders for the first time. On January 9, the procurement platform extended operations to Fangchenggang, a coastal municipality within the autonomous region of Guangxi Zhuang
